Comparison of the efficacy of ambroxol hydrochloride and N‑acetylcysteine in the treatment of children with bronchopneumonia and their influence on prognosis

Liu,Hongbo; Wang,Wenxiao; Gao,Xingjuan

doi:10.3892/etm.2020.9260

Comparison of the efficacy of ambroxol hydrochloride and N‑acetylcysteine in the treatment of children with bronchopneumonia and their influence on prognosis

Authors:
- Hongbo Liu
- Wenxiao Wang
- Xingjuan Gao
View Affiliations

Affiliations: Department of Pediatrics, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China
Published online on: October 1, 2020 https://doi.org/10.3892/etm.2020.9260
Article Number: 130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the efficacy of ambroxol hydrochloride and N‑acetylcysteine in the treatment of children with bronchial pneumonia and their influence on prognosis. A total of 120 children with bronchial pneumonia, admitted to The Affiliated Yantai Yuhuangding Hospital of Qingdao University from July 2015 to August 2018, were enrolled in the study. Among them, 58 children were treated with N‑acetylcysteine and comprised the experimental group, and 62 children were treated with ambroxol hydrochloride and comprised the control group. Children's physical signs (such as fever, short breath, cough and pulmonary rales) and the adverse reactions to treatment were observed, and the disappearance time of the signs was recorded. In addition, the cellular immune function indicators and the quality of life after treatment were investigated. There was no significant difference in clinical data between the two groups (P>0.05). The effective rate in the experimental group was significantly higher than that in the control group (P<0.05). The disappearance time of symptoms, such as fever, cough, asthma and rales in the lung, was significantly shorter in the experimental group than that in the control group (P<0.05). The hospitalization time of patients in the experimental group was shorter than that in the control group (P<0.05). After treatment, immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM) and complement C3 were significantly increased in the experimental group (P<0.01), and the IgA and IgG in the experimental group were significantly higher than those in the control group (P<0.01). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group (P<0.05). In conclusion, N‑acetylcysteine has a significant effect on the treatment of bronchopneumonia in children providing a quick relief from symptoms, such as lung rales, and therefore is worthy of use in clinic.

View Figures

View References

1	Dhanapal CK, Mathew J, Madhusudhan S, Manavalan R and Roy V: A Hospital Based study on some Clinico-epidemiological aspect of bronchopneumonia among infants and young children. Int J Chem Sci, 2009 doi: 10.1234/jgpt.v1i1.37.
2	Zhang XL, Ji W, Ji ZH, Ding YF, Zhu H, Yan YD, Huang YP, He YX, Ye JX and Ji XQ: Epidemiological study on respiratory syncytial virus and its bronchopneumonia among children in Suzhou. Zhonghua Yu Fang Yi Xue Za Zhi. 41:371–374. 2007.(In Chinese). PubMed/NCBI
3	Chang CC, Cheng AC and Chang AB: Over the counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 10(CD006088)2014.PubMed/NCBI View Article : Google Scholar
4	Che XY: Effect of aerosol inhalation of ipratropium bromide in combined with budesonide and terbutaline on the cytokines in children with bronchopneumonia. J Hainan Med Univ. 22:65–68. 2016.
5	Chunyun Z: Atomization-based inhalation-induced cough reflex in treating chronic obstructive pulmonary disease. J Trop Med, 2010.
6	Zhou WF, Chen Q, Jin MF, Ji ZH, Zhang MZ, Li HM, Liu FJ and Ji W: The diagnostic accuracy of high-mobility group box 1 protein and twelve other markers in discriminating bacterial, viral and co-infected bronchial pneumonia in Han children. Microbiol Immunol. 55:279–288. 2011.PubMed/NCBI View Article : Google Scholar
7	Pairet M, Engelmann P, Von Nicolai H, Champeroux P, Richard S, Rauber G and Engelhardt G: Ambroxol improves the Broncho-spasmolytic activity of clenbuterol in the guinea-pig. J Pharm Pharmacol. 49:184–186. 2011.PubMed/NCBI View Article : Google Scholar
8	Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, Götz M and Dimou L: Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia. 61:273–286. 2013.PubMed/NCBI View Article : Google Scholar
9	Li YQ, Yuan W and Zhang SL: Clinical and experimental study of xiao er ke cuan ling oral liquid in the treatment of infantile bronchopneumonia. Zhongguo Zhong XI Yi Jie He Za Zhi. 12:719–721, 737, 708. 1992.(In Chinese). PubMed/NCBI
10	Chen X, Liu Z, Ge X, Luo X, Huang S, Zhou Y, Li D, Cheng H, Li L, Huang L, et al: Associations between manganese exposure and multiple immunological parameters in manganese-exposed workers healthy cohort. J Trace Elem Med Biol. 59(126454)2020.PubMed/NCBI View Article : Google Scholar
11	Olivieri A, Carli GFD, Panebianco R, et al: The use of SF-36 questionnaire for the evaluation of quality of life of patients with chronic bronchitis undergoing to antibiotic prophylaxis of acute exacerbations. Qual Life Res. 3:88–89. 1994.
12	Mosbah AA, Abdellatif NA, Sorour EI and Awadallah MF: Serum Sp-D levels as a biomarker of lung injury in Children suffering of bronchopneumonia. J Egypt Soc Parasitol. 42:25–32. 2012.PubMed/NCBI View Article : Google Scholar
13	Miyata T, Ishii T, Sugiyama N, Okano Y, Nishi N, Takahama K, Ogasawara S, Oda Y, Yokoyama K, Murata Y, et al: Effect of N-acetylneuraminic acid on respiratory tract secretion and inflammation in the bronchitic rabbit. Arch Int Pharmacodyn Ther. 304:277–289. 1990.PubMed/NCBI
14	Trastotenojo MS, Harsoyo N, Sachro AD, Soemantri AG and Said HW: Use of acetyl cysteine in respiratory tract disease in children. Paediatr Indones. 24:1–10. 1984.PubMed/NCBI
15	Zafarullah M, Li WQ, Sylvester J and Ahmad M: Molecular mechanisms of N-acetylcysteine actions. Cell MolLife Sci. 60:6–20. 2003.PubMed/NCBI View Article : Google Scholar
16	Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA and Wright PE: A trial of antioxidants N-acetylcysteine and Procysteine in ARDS. Chest. 112:164–172. 1997.PubMed/NCBI View Article : Google Scholar
17	Hermeyer K, Buchenau I, Thomasmeyer A, Baum B, Spergser J, Rosengarten R and Hewicker-Trautwein M: Chronic pneumonia in calves after experimental infection with Mycoplasma bovis strain 1067: Characterization of lung pathology, persistence of variable surface protein antigens and local immune response. Acta Vet Scand. 54(9)2012.PubMed/NCBI View Article : Google Scholar
18	Rong-Xin J, Yi Y and Pediatrics DO: Comparison of curative effects of N-acetylcysteine and ambroxol hydrochloride in treatment of children with bronchial pneumonia and the effect on immune function and clinical symptoms. Maternal Child Health Care China, 2018.